Literature DB >> 6635123

Oral physostigmine in Alzheimer's disease.

K L Davis, R C Mohs, B M Davis, T B Horvath, B S Greenwald, W G Rosen, M I Levy, C A Johns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6635123

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN： 0048-5764


× No keyword cloud information.
  3 in total

1.  Studies on new, centrally active and reversible acetylcholinesterase inhibitors.

Authors:  F Arnal; L J Coté; S Ginsburg; G D Lawrence; A Naini; M Sano
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

Review 2.  Periodic health examination, 1991 update: 1. Screening for cognitive impairment in the elderly. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-02-15       Impact factor: 8.262

3.  CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons.

Authors:  Maitane Ortiz-Virumbrales; Cesar L Moreno; Ilya Kruglikov; Paula Marazuela; Andrew Sproul; Samson Jacob; Matthew Zimmer; Daniel Paull; Bin Zhang; Eric E Schadt; Michelle E Ehrlich; Rudolph E Tanzi; Ottavio Arancio; Scott Noggle; Sam Gandy
Journal:  Acta Neuropathol Commun       Date:  2017-10-27       Impact factor: 7.801
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.